Rate of response to CyBorD is ‘truly remarkable’

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 12
Volume 17
Issue 12

There was a very rapid response [to CyBorD], which has been typical when you incorporate bortezomib into the initial regimens,” commented Dr. Anderson, from the Dana-Farber Cancer Institute in Boston.

There was a very rapid response [to CyBorD], which has been typical when you incorporate bortezomib into the initial regimens,” commented Dr. Anderson, from the Dana-Farber Cancer Institute in Boston.

“As is 100% of the time true, as far as I know, the adverse cytogenetics- del(13) and t(4;14)-are no longer relevant in the context of bortezomib- containing initial therapies.” The rate of complete or near-complete response increased from 39% to 46% to 72%, going from the intent-to-treat population to patients who completed treatment to transplant recipients, Dr. Anderson observed, characterizing the rates achieved as “truly remarkable.”

“I believe this is another example of a very active bortezomib-containing new therapy,” he said.

 

The main article can be found here:
CyBorD combo supports stem cell collection in newly diagnosed multiple myeloma

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.